Icon
+91 94997 68112
Login Register

Adzenys XR- ODT - (3.1,6.3,9.4,12.5,15.7,18.8 mg; Tablet Extended)

Amphetamine Neos Therapeutics
3.1,6.3,9.4,12.5,15.7,18.8 mg; Tablet Extended
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
 None
Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Yes
******* ** *** ***** ** **** **** ** **** ******* ***. ‘***, ‘*** (*** ***** ******** ** **** **, ****); ‘*** (**** *, ****) *** *** ************ *********. ** ****** **** **** ******* ******* ** *** ****.
Adzenys XR- ODT Patent 1 Patent 2 Patent 3 Patent 4
******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ********* ***** *, **** ******* ******** ** **** *, ****
  1. **** **, **** : ******* ******** **** ************ ***** *** **** ** **** ******* '***. ‘***, ‘*** (*** ***** ******** ** **** **, ****); ‘*** (**** *, ****) ,
  2. *** *, **** : **** ************ ***** * **** ******* ******* ** ******** ***** ** ********.
  3. *** **, **** : ********** ********* **** *******

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.